Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346639 | 0.94 | MMP13 (0.31) | KMT2AMMP13 | |
| SCHEMBL7059643 | 0.94 | KMT2A (0.33) | KMT2AMEN1MMP13 | |
| SCHEMBL7058728 | 0.92 | MMP13 (0.40) | MMP13MMP3 | |
| SCHEMBL7060192 | 0.89 | GRIN2B (0.32) | KMT2AMEN1ALDH1A1MMP13MMP3 | |
| SCHEMBL7657258 | 0.88 | F2 (0.32) | KMT2AMEN1ALDH1A1MMP13MMP8 | |
| SCHEMBL7057176 | 0.88 | F2 (0.32) | KMT2AMEN1ALDH1A1MMP13MMP8 | |
| SCHEMBL7057619 | 0.87 | ALDH1A1 (0.36) | KMT2AMEN1ALDH1A1MMP13 | |
| SCHEMBL7056675 | 0.86 | KMT2A (0.33) | KMT2AMEN1ALDH1A1MMP13MMP8 | |
| SCHEMBL7059005 | 0.86 | ALDH1A1 (0.36) | KMT2AMEN1ALDH1A1MMP13MMP8 | |
| SCHEMBL7054421 | 0.86 | ALDH1A1 (0.36) | KMT2AMEN1ALDH1A1MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | KMT2A 1432/4885MEN1 3998/4885ALDH1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.